NYXOAH SA

Nyxoah shares rebound 3.53% to €0.74—value‑seeking investors eye the company’s low price, neuro‑stimulation tech, and upcoming clinical data.

Nyxoah SA’s 3.53% uptick at €0.73 highlights potential undervaluation amid steep 52‑week swings—ideal for investors eyeing niche neuro‑stimulation tech.

Nyxoah’s shares slide steeply amid weak liquidity, limited FDA clearance and a sparse product line—investors face high risk as the neuro‑stimulation firm’s prospects dim.